Cordoba JF et al. [34] study illustrated that there is shorter and worse OS for TTF1-negative NSCLC patients, regardless of treatment intention, and a lower frequency of EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.